Wanbangde Pharmaceutical Holding Group Co., Ltd. (SHE:002082)
China flag China · Delayed Price · Currency is CNY
9.77
-0.35 (-3.46%)
Nov 13, 2026, 3:04 PM CST

SHE:002082 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
852.821,1171,4271,5311,7701,923
Other Revenue
0.710.7116.1110.5116.467.86
853.521,1171,4431,5421,7861,931
Revenue Growth
-38.44%-22.59%-6.39%-13.69%-7.47%-85.91%
Cost of Revenue
492.17737.1847.18918.18852.57999.27
Gross Profit
361.35380.23596.19623.76933.85931.33
Selling, General & Admin
330.19374.84443.02458.13579.71571.77
Research & Development
46.4859.1659.8753.9859.176.2
Other Operating Expenses
62.0815.1317.5417.8923.4820.43
Operating Expenses
487.28519.61519.54553.57701.27720.65
Operating Income
-125.92-139.3876.6570.19232.58210.69
Interest Expense
-39.1-38.08-38.5-46.48-33.2-35.6
Interest & Investment Income
12.0711.7918.975.1910.75235.76
Currency Exchange Gain (Loss)
1.81.8-0.05-4.53-0.82-0.93
Other Non Operating Income (Expenses)
-1.48-2-1.84-1.41-0.74-1.27
EBT Excluding Unusual Items
-152.63-165.8655.2322.96208.58408.65
Impairment of Goodwill
-----67.78-19.27
Gain (Loss) on Sale of Investments
5.6910.452.94-1.83-0.56-2.39
Gain (Loss) on Sale of Assets
0.30.615.740.12-0.95-1.21
Asset Writedown
-7.3-6.13-21.75-2.88-22.5-28.09
Other Unusual Items
14.131.726.811.56-16.663.46
Pretax Income
-139.81-159.2358.9529.93100.13361.14
Income Tax Expense
17.7812.6713.713.626.43199.98
Earnings From Continuing Operations
-157.58-171.945.2526.3373.71161.16
Minority Interest in Earnings
11.134.6610.1922.8819.555.35
Net Income
-146.45-167.2455.4449.2193.26166.51
Net Income to Common
-146.45-167.2455.4449.2193.26166.51
Net Income Growth
--12.67%-47.23%-43.99%-41.56%
Shares Outstanding (Basic)
743619616615622617
Shares Outstanding (Diluted)
743619616615622617
Shares Change
52.09%0.55%0.15%-1.06%0.82%1.73%
EPS (Basic)
-0.20-0.270.090.080.150.27
EPS (Diluted)
-0.20-0.270.090.080.150.27
EPS Growth
--12.50%-46.67%-44.44%-42.55%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
712.55302.3323.11-201.59-406.88-263.42
Free Cash Flow Per Share
0.960.490.04-0.33-0.65-0.43
Dividend Per Share
---0.0800.120-
Dividend Growth
----33.33%-40.00%-
Gross Margin
42.34%34.03%41.30%40.45%52.28%48.24%
Operating Margin
-14.75%-12.47%5.31%4.55%13.02%10.91%
Profit Margin
-17.16%-14.97%3.84%3.19%5.22%8.63%
Free Cash Flow Margin
83.48%27.06%1.60%-13.07%-22.78%-13.64%
EBITDA
-24.78-38.26177.72163.98337.3305.12
EBITDA Margin
-2.90%-3.43%12.31%10.63%18.88%15.80%
D&A For EBITDA
101.15101.11101.0793.79104.7294.43
EBIT
-125.92-139.3876.6570.19232.58210.69
EBIT Margin
-14.75%-12.47%5.31%4.55%13.02%10.91%
Effective Tax Rate
--23.25%12.04%26.39%55.37%
Revenue as Reported
853.521,1171,4431,5421,7861,931
Advertising Expenses
-0.861.493.731.324.86